Brolucizumab-early real-world experience: BREW study (Jul, 10.1038/s41433-020-1111-x, 2020)

被引:0
|
作者
Sharma, Ashish
Kumar, Nilesh
Parachuri, Nikulaa
Sadda, Srinivas R.
Corradetti, Giulia
Heier, Jeffrey
Chin, Adam T.
Boyer, David
Dayani, Pouya
Arepalli, Sruthi
Kaiser, Peter
机构
[1] Lotus Eye Hospital and Institute,
[2] Doheny Eye Institute Los Angeles CA USA,undefined
[3] Department of Ophthalmology David Geffen School of Medicine,undefined
[4] UCLA,undefined
[5] Ophthalmic Consultants of Boston,undefined
[6] Tufts Medical Center,undefined
[7] Retina Vitreous Associates Medical Group,undefined
[8] Cole Eye Institute,undefined
[9] Cleveland Clinic,undefined
关键词
D O I
10.1038/s41433-020-01351-7
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
引用
收藏
页码:1286 / 1286
页数:1
相关论文
共 3 条
  • [1] Brolucizumab—early real-world experience: BREW study
    Ashish Sharma
    Nilesh Kumar
    Nikulaa Parachuri
    Srinivas R. Sadda
    Giulia Corradetti
    Jeffrey Heier
    Adam T. Chin
    David Boyer
    Pouya Dayani
    Sruthi Arepalli
    Peter Kaiser
    Eye, 2021, 35 : 1045 - 1047
  • [2] Correction: Brolucizumab—early real-world experience: BREW study
    Ashish Sharma
    Nilesh Kumar
    Nikulaa Parachuri
    Srinivas R. Sadda
    Giulia Corradetti
    Jeffrey Heier
    Adam T. Chin
    David Boyer
    Pouya Dayani
    Sruthi Arepalli
    Peter Kaiser
    Eye, 2021, 35 (4) : 1286 - 1286
  • [3] REALMS study: real-world effectiveness and safety of fingolimod in patients with relapsing-remitting multiple sclerosis in Portugal (September, 10.1007/s10072-020-04726-6, 2020)
    Batista, S.
    Nunes, C. C.
    Cerqueira, J. J.
    Silva, Ana Martins
    de Sa, J. Correia
    Ferreira, J.
    Mendonca, M. T.
    Pinheiro, J.
    Salgado, V.
    Correia, A. S.
    Sequeira, J.
    Costa, A.
    Sousa, L.
    NEUROLOGICAL SCIENCES, 2021, 42 (02) : 767 - 767